Working Student - Event/Marketing
About the job
- Strong proficiency in Microsoft Office.
- Highly organized and structured working style, with the ability to work independently.
- Familiarity with social media.
- Excellent written and oral English communication skills.
- Manage projects independently, either in full or in part.
- Assist with the design, planning, preparation, and follow-up of international events.
- Create reports to document the quality of events.
- Oversee online events.
- Act as the intermediary between event organizers and the European sales team.
- Knowledge of or interest in events, media, marketing, or tourism.
- Interest in learning about new things and working collaboratively within a team.
About the company
Bruker makes analytical and diagnostic instruments used by researchers and industries. Its products help analyze materials and biological samples to reveal chemical structure, composition, and properties, with notable roots in nuclear magnetic resonance (NMR) technology and a broad portfolio beyond that field. The company works by designing and selling instruments such as analytical tools that collect data from samples (for example, signals from nuclei in NMR or other spectroscopic methods) and provide insights to researchers. Bruker differentiates itself through a long history of developing advanced technologies, a focus on innovation in scientific instrumentation, and a global product range serving life sciences, materials science, and environmental analysis, supported by steady investment in research and development. Its goal is to equip researchers and industries with reliable tools to push the boundaries of what is possible in science and discovery.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Billerica, Massachusetts
Founded
1960
Get referred to Bruker
See people who can refer or advise you
Simplify's Take
What believers are saying
- September 28, 2026 timsUltra AIP and timsOmni launches deepen proteomics and oligonucleotide workflows.
- August 10, 2026 MIMETAS deal expands Bruker into human-relevant drug discovery models.
- UC Berkeley ordered over $6 million of Bruker NMR systems, delivering 2027 revenue.
What critics are saying
- Bruker’s first-half 2026 organic revenue declined 0.8%, exposing fragile demand recovery.
- Academic spending stayed soft in 2026, while tariffs and currency pressured results.
- If MIMETAS and fusion remain niche, Bruker’s acquisition-heavy strategy destroys capital returns.
What makes Bruker unique
- Bruker owns timsTOF proteomics, NMR, microscopy, and microphysiological systems under one platform.
- Bruker’s August 31 XFlash 7200 FIRE raises SEM-EDS throughput beyond conventional detector designs.
- Bruker’s BEST superconductors supply ITER, Wendelstein 7-X, CERN, and fusion demonstrators.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
401(k) Retirement Plan
401(k) Company Match
Employee Stock Purchase Plan
Paid Vacation
Paid Sick Leave
Paid Holidays
Disability Insurance
Life Insurance
Dental Insurance
Flexible Work Hours
Employee Discounts
Growth & Insights and Company News
6 month growth
↑ 13%1 year growth
↑ 13%2 year growth
↑ 13%Bruker advances functional proteomics with novel timsUltra AIP and timsOmni workflows for drug discovery & development and disease biology research. Sep 28 2026 12:00 BST * MultiDIA-PASEF significantly increases protein sequence coverage on timsUltra AIP * ProteoScape connects PASEF discovery with rapid prm-PASEF target validation * Spectronaut(R) AI transfer learning accelerates adaptation to new MS capabilities * Guided PASEF EXciD enables high-throughput glycopeptide characterization * Integrated HDX-MS workflows advance protein conformation and interaction studies * timsOmni(TM) enables RNA and DNA top-down structural and native RNA analysis SINGAPORE-(BUSINESS WIRE)-Sep. 28, 2026- At the Human Proteome Organization World Congress 2026, Bruker Corporation (Nasdaq: BRKR) today announced unique new timsUltra AIP and timsOmni workflows for deeper protein-sequence coverage, targeted validation, mobility-resolved glycopeptide characterization, structural proteomics, and oligonucleotide analysis. Multi-enzyme dia-PASEF provides additional peptide information for investigations of isoforms and proteoforms, while ProteoScape workflows connect PASEF discovery with prm-PASEF target validation on the same timsTOF platform. Novel timsOmni and integrated HDX-MS workflows extend structural analysis to glycopeptides, proteins, and nucleic acids.
Bruker Corporation receives order from University of California, Berkeley for high-field nmr systems for major upgrade of Magnetic Resonance research infrastructure. Published on 09/21/2026 at 09:36 am EDT S&P Capital IQ Bruker Corporation announced a multi-system order from University of California, Berkeley for high-field Nuclear Magnetic Resonance (NMR) instrumentation at the Pines Magnetic Resonance Center. The investment will enhance access to next-generation NMR technologies, including 800 MHz?class instrumentation. The investment is centered on a Bruker AV NEO-X 800 MHz spectrometer equipped with a cryogenically cooled MAS CryoProbe, complemented by several additional NMR systems and upgrades supporting solid-state, solution-state and Dynamic Nuclear Polarization (DNP) research. The UC Berkeley NMR order exceeds USD 6 million and is expected to be delivered in 2027. (C) S&P Capital IQ - 2026
Market for Registrant’s Common Equity, Related Shareholder Matters and Issuer Purchases of Equity Securities
Unaudited Condensed Consolidated Balance Sheets as of June 30, 2024 and December 31, 2023
Bruker advances whole-organism 3D imaging with enhanced tissue-clearing workflows. Bruker Corporation today announced a strategic collaboration with Translucence Biosystems, Inc., a leading provider of tissue-clearing solutions, to expand its workflow for cleared tissue imaging. Through the combined use of Translucence's Universal Tissue Clearing Kit alongside Bruker's light-sheet microscopy and data processing platforms, researchers can move from sample preparation to high-resolution, analysis-ready 3D datasets with greater efficiency and ease. Industry focus ebook - Life Science Microscopy (2nd edition) ebook. Download the latest expert interviews, articles, and news in Life Science Microscopy. The Universal Tissue Clearing Kit is designed to support user-defined antibodies and requires no specialized equipment. Its accessibility and flexibility enable researchers to implement standardized clearing workflows in typical laboratory environments while reducing variability. Bruker's MuVi SPIM and LCS SPIM light-sheet microscopes are optimized for 3D imaging of cleared samples, from intricate tissue structures to entire organisms. These systems are supported by a software suite that offers high-speed registration and fusion of large, multi-view datasets. Bruker also provides scalable data management, visualization, and processing with its Acquifer HIVE platform. Together, these complementary technologies support a streamlined workflow for cleared tissue imaging, enabling researchers to align sample preparation, imaging, and data processing steps more effectively. This approach facilitates consistent generation of high-quality 3D datasets while improving usability, reproducibility, and scalability across a range of biological research applications. News Medical developed its Universal Tissue Clearing Kit to make high-quality 3D histology more consistent and broadly accessible across different sample types, By combining this foundation with Bruker's imaging and data capabilities, News Medical can extend the impact of its approach and provide researchers with a more powerful and cohesive solution for whole-organ analysis." Damian Wheeler, Ph.D., Co-Founder and CEO, Translucence Biosystems "Today's researchers are increasingly looking for complete workflows," added Xiaomei Li, Ph.D., Senior Vice President and General Manager of Bruker Fluorescence Microscopy. "This collaboration simplifies 3D imaging workflow, improves reproducibility, and enables researchers to generate meaningful biological insights more efficiently. We believe this partnership will help accelerate discoveries across both basic research and emerging translational applications." Be the first to rate this article